Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Summit Corporation plc Stories

2012-04-24 02:28:56

MDA Supported Reformulation of Utrophin-Boosting Compound TUCSON, Ariz., April 24, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association announced today that SMT C1100, an experimental drug for Duchenne muscular dystrophy (DMD), has received approval from regulatory agencies in the United Kingdom to move from laboratory to human testing, starting with healthy human volunteers. (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) The drug is designed to...

2008-07-22 09:01:13

NOVATO, Calif. and OXFORD, England, July 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive worldwide licensing agreement for Summit's novel preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat the fatal genetic disorder Duchenne muscular dystrophy (DMD). Under the terms of the licensing agreement, Summit will receive an...